...in a key leadership role focused on early development and innovation. Baskin-Bey was CMO of Innocrin Pharmaceuticals Inc....

...enrolling women with unresectable, locally advanced or metastatic estrogen receptor-positive or triple-negative breast cancer (TNBC). Innocrin Pharmaceuticals Inc....
...ORR) and progression-free survival (PFS) Status: Phase I/II data Milestone: Additional Phase I/II data (2017) Alex Himes VT-464 Innocrin Pharmaceuticals Inc. Androgen...

...of translational sciences at the California Institute for BioMedical Research (La Jolla, Calif.). Cancer play Innocrin Pharmaceuticals Inc....

...in 28-day cycles in about 148 chemotherapy-naive patients progressing on Xtandi enzalutamide or Zytiga abiraterone. Innocrin Pharmaceuticals Inc....

...Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. Innocrin Pharmaceuticals Inc....

...the round to $19 million. Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Innocrin Pharmaceuticals Inc....
...of Oncology 7 1802-7 (2013) Shaffer, C. "Metallic strategy." BioCentury 15 (Nov. 3, 2014) Sidebars Innocrin Pharmaceuticals Inc....

...with the financing, Viamet said it would spin its prostate cancer assets out into newco Innocrin Pharmaceuticals Inc....

...it will spin out its prostate cancer program to existing investors in a newco called Innocrin Pharmaceuticals...